San Diego-based Optimer Pharmaceuticals said today that it has named Kurt Hartman as its General Counsel and Access. Hartman was most recently at Eisai Inc., and also has served at Boehringer Ingelheim, Maxim Pharmaceuticals, Amgen, and Kaiser Permanente. As part of the role, Optimer said Hartman will lead development and execution of Optimer's market access strategies for its lead product candidate, fidaxomicin. Optimer's fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).